3.8 Article

Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors

Related references

Note: Only part of the references are listed.
Article Pediatrics

Cystic fibrosis newborn screening: the importance of bloodspot sample quality

Iolo Doull et al.

Summary: The study aimed to determine the causes of false negative cases in CF newborn screening and found that the majority of false negatives were associated with poor quality DBS samples. Improving the quality of DBS samples would be the optimal way to enhance the sensitivity of the CF NBS programme.

ARCHIVES OF DISEASE IN CHILDHOOD (2021)

Article Medical Laboratory Technology

Galactose-1-phosphate uridyltransferase dried blood spot quality control materials for newborn screening tests

Barbara W. Adam et al.

CLINICAL BIOCHEMISTRY (2015)

Article Pediatrics

Thirty-years of screening for cystic fibrosis in East Anglia

Jacqui Calvin et al.

ARCHIVES OF DISEASE IN CHILDHOOD (2012)

Article Genetics & Heredity

Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: Challenges in newborn dried blood spot screening

Bradford L. Therrell et al.

MOLECULAR GENETICS AND METABOLISM (2012)

Article Medical Laboratory Technology

The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States

B. W. Adam et al.

CLINICAL BIOCHEMISTRY (2011)

Article Pediatrics

Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening

Michael J. Rock et al.

PEDIATRIC PULMONOLOGY (2011)

Article Respiratory System

A survey of newborn screening for cystic fibrosis in Europe

Kevin W. Southern et al.

JOURNAL OF CYSTIC FIBROSIS (2007)